A study assessing tolerability and safety of nintedanib at a low starting dosage (100 mg BID) in patients with IPF
Latest Information Update: 20 Sep 2019
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
Most Recent Events
- 20 Sep 2019 New trial record